Contact this trialFirst, we need to learn more about you.
Immunotherapy
BMS-986288 + Nivolumab for Cancer
Recruiting1 awardPhase 1 & 2
Ottawa, Ontario
This trial is testing a new drug, BMS-986288, alone and with Nivolumab, to see if they are safe and tolerable for patients with advanced solid tumors. The goal is to help the immune system fight cancer more effectively.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service